Nwam LLC Buys Shares of 910,476 Anavex Life Sciences Corp. (NASDAQ:AVXL)

Nwam LLC purchased a new position in Anavex Life Sciences Corp. (NASDAQ:AVXL) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 910,476 shares of the biotechnology company’s stock, valued at approximately $5,172,000. Nwam LLC owned 1.07% of Anavex Life Sciences as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. The Manufacturers Life Insurance Company raised its stake in Anavex Life Sciences by 8.5% during the second quarter. The Manufacturers Life Insurance Company now owns 30,510 shares of the biotechnology company’s stock worth $129,000 after buying an additional 2,401 shares during the last quarter. Private Advisor Group LLC lifted its stake in shares of Anavex Life Sciences by 10.3% in the 3rd quarter. Private Advisor Group LLC now owns 47,413 shares of the biotechnology company’s stock valued at $269,000 after purchasing an additional 4,442 shares during the period. Fiduciary Alliance LLC boosted its position in shares of Anavex Life Sciences by 45.2% during the 2nd quarter. Fiduciary Alliance LLC now owns 19,275 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 6,000 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in Anavex Life Sciences by 64.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 16,309 shares of the biotechnology company’s stock worth $93,000 after purchasing an additional 6,366 shares during the period. Finally, Atria Investments Inc acquired a new stake in Anavex Life Sciences during the third quarter worth approximately $76,000. 31.55% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and set a $40.00 price target on shares of Anavex Life Sciences in a report on Monday, November 4th.

Anavex Life Sciences Trading Down 1.8 %

NASDAQ:AVXL opened at $8.86 on Friday. The firm has a fifty day simple moving average of $6.32 and a two-hundred day simple moving average of $5.49. Anavex Life Sciences Corp. has a 12 month low of $3.25 and a 12 month high of $10.45. The stock has a market capitalization of $751.29 million, a price-to-earnings ratio of -18.04 and a beta of 0.60.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.